Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-22T07:30:02.989Z Has data issue: false hasContentIssue false
  • English
  • Français

Making Advances Where It Matters: Improving Outcomes in Mood and Anxiety Disorders

Published online by Cambridge University Press:  07 November 2014

Robert N. Golden
Robert N. Golden*
Affiliation:
Dr. Golden is professor and chair of psychiatry at the, University of North Carolina School of Medicineat Chapel Hill.
*
University of North Carolina-Chapel Hill, Department of Psychiatry, CB#7160, Chapel Hill, NC, 27599-7160. Tel: 919-966-4738; Fax:, 919-966-8623; E-mail;, [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

Mood and anxiety disorders are among the most prevalent psychiatric illnesses and are associated with considerable morbidity and mortality. Selective serotonin reuptake inhibitors (SSRIs) are safe and effective treatments for major depression and anxiety disorders, and have become the most widely prescribed antidepressants worldwide. However, several issues limit SSRI treatment outcomes. Although SSRIs have a wider therapeutic margin and a milder side-effect profile compared to earlier antidepressants, even minor SSRI side effects can have a major impact on treatment outcomes by interfering with patient compliance. Nausea is one of the most common early SSRI side effects, and advances in SSRI delivery systems can diminish this. A controlled-release formulation of paroxetine targets the site of absorption for a more distal region of the small intestine, thereby avoiding the stimulation of upper gastrointestinal serotonin receptors that mediate nausea. The sustained-release characteristics also reduce the amplitude in blood level peaks and troughs, which may lead to diminished side effects and enhanced efficacy. Sexual side effects and weight gain are important sustained SSRI side effects, which affect compliance during continuation and maintenance phases of treatment. Several strategies address SSRI sexual side effects, including the use of adjunctive medication and/or manipulations in the scheduling of drug administration. Depression negatively impacts the management of many medical illnesses, including cardiovascular disease, cancer, and infectious diseases. The recognition and treatment of depression leads to improved outcomes in the management of breast cancer. Prophylactic SSRI treatment significantly reduces the incidence of interferon-associated depression and enhances completion rates in malignant melanoma.

Type
Research Article
Information
CNS Spectrums , Volume 9 , Issue S4 , 2004 , pp. 14 - 22
Copyright
Copyright © Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.World Health Organization. World Health Report 2001: Mental Health: New Understanding, New Hope. Geneva: WHO, 2001. Available at: http://www.who.int/whr2001/2001/main/en/chapter2/002e1.htm. Accessed March 23, 2004.Google Scholar
2.Von Korff, M, Goldberg, D. Improving outcomes in depression. BMJ. 2001;323:948–949.Google Scholar
3.Goldberg, D, Privet, M, Ustun, B, Simon, G, Linden, M. The effects of detection and treatment on the outcome of major depression in primary care: a naturalistic study in 15 cities. Br J Gen Pract. 1998;48(437):1840–1844.Google Scholar
4.World Health Organization. Global Burden of Disease: 2000. Geneva: WHO, 2001. Available at: http://www.who.int/whr2001/2001/main/en/chapter2/002.htm. Accessed March 24, 2004.Google Scholar
5.Kessler, RC, Berglund, P, Demler, O. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–3105.Google Scholar
6.Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed. rev. Washington, DC: American Psychiatric Association; 2000.Google Scholar
7.Goodwin, FK, Jamison, KR. Suicide. In: Manic-Depressive Illness. New York, NY: Oxford University Press; 1990:227–244.Google Scholar
8.Regier, DA, Rae, DS, Narrow, WE, Kaelber, CT, Schatzberg, AF. Prevalence of anxiety disorders and their comorbidity with mood and addictive Disorders. Br J Psychiatry Suppl. 1998;43:24–28.Google Scholar
9.Weissman, MM, Klerman, GL, Markowitz, JS, Ouellette, R. Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med. 1989;321(18):1209–1214.Google Scholar
10.Dunham, NC, Sager, MA. Functional status, symptoms of depression, and the outcomes of hospitalization in community-dwelling elderly patients. Arch Fam Med. 1994;3(8):676–680.Google Scholar
11.Perez-Stable, EJ, Miranda, J, Munoz, RF, Ying, YW. Depression in medical outpatients. Underrecognition and misdiagnosis. Arch Intern Med. 1990;May(5):1083–1088.Google Scholar
12.Rovner, BW, German, PS, Brant, LJ, Clark, R, Burton, L, Folstein, M. Depression and Mortality in Nursing Homes. JAMA. 1991;265(8):993–996.Google Scholar
13.Katon, W, von Korff, M, Lin, E, Bush, T, Ormel, J. Adequacy and duration of antidepressant treatment in primary care. Med Care. 1992;30(1):67–76.Google Scholar
14.Evans, DL, Staab, J, Ward, H. Depression in the medically ill: management considerations. Depress Anxiety. 1997;4:199–208.Google Scholar
15.Cassem, EH. Depressive disorders in the medically ill. An overview. Psychosomatics. 1995;36(2):S2–S10.Google Scholar
16.Katon, W, Sullivan. Depression and chronic medical illness. J Clin Psychiatry. 1990;51(S3-11):12-4.Google Scholar
17.Gotham, AM, Brown, RG, Marsden, CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry. 1996;49(4):381–389.Google Scholar
18.Starkstein, SE, Preziosi, TJ, Forrester, AW, Robinson, RG. Specificity of affective and autonomic symptoms of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990;53(10):869–873.Google Scholar
19.Cummings, JL. Depression and Parkinson's disease: a review. Am J Psychiatry. 1992;149(4):443–454.Google Scholar
20.Liu, CY, Wang, SJ, Fuh, JL, Lin, CH, Yang, YY, Liu, HC. The correlation of depression with functional activity in Parkinson's disease. J Neurol. 1997;244(8):493–498.Google Scholar
21.Frasure-Smith, N, Lesperance, F, Talajic, M. Depression following myocardial infarction: impact on 6-month survival. JAMA. 1993;270(15):1819–1825.Google Scholar
22.Glassman, AH, O'Connor, CM, Califf, RM, et al, for the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701–709.Google Scholar
23.Leserman, J, Jackson, ED, Petitto, JM. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med. 1999;61(3):397–406.Google Scholar
24.Fauci, AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science. 1993;262:1011–1018.Google Scholar
25.Burack, JH, Barrett, DC, Stall, RD, Chesney, MA, Ekstrand, ML, Coates, TJ. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA. 1993;270:2568–2573.Google Scholar
26.Zorilla, EP, McKay, JR, Luborsky, L, Schmidt, K. Relation of stressors and depressive symptoms to clinical progression of viral illness. Am J Psychiatry. 1996;153:626–635.Google Scholar
27.Page-Shafer, K, Delorenze, GN, Satariano, W, Winkelstein, W Jr.Comorbidity and survival in HIV-infected men in the San Francisco men's health survey. Ann Epidemiol. 1996;6:420–430.Google Scholar
28.Leserman, J, Petitto, JM, Perkins, DO, Folds, JD, Golden, RN, Evans, DL. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. Arch Gen Psychiatry. 1997;54:279–285.Google Scholar
29.Leserman, J, Petitto, JM, Gu, H. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med. 2002;32(6):1059–1073.Google Scholar
30.Williams, JB, Rabkin, JG, Remien, RH, Gorman, JM, Ehrhardt, AA. Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus Infection. II. Standardized clinical assessment of current and lifetime psychopathology. Arch Gen Psychiatry. 1991;48(2):124–130.Google Scholar
31.Perry, S, Jacobsberg, L, Card, CA, Ashman, T, Frances, A, Fishman, B. Severity of Psychiatric Symptoms After HIV Testing. Am J Psychiatry. 1993;150(5):775–779.Google Scholar
32.Perkins, DO, Stern, RA, Golden, RN, Murphy, C, Naftolowitz, D, Evans, DL. Mood disorders in HIV infection: Prevalence and risk factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry. 1994;151(2):233–236.Google Scholar
33.Lipsitz, JD, Williams, JB, Rabkin, JG, et al.Psychopathology in male and female intravenous drug users with and without HIV infection. Am J Psychiatry. 1994;151(11):1662–1668.Google Scholar
34.Brown, GR, Rundell, JR. Prospective study of psychiatric morbidity in HIV-seropositive women without AIDS. Gen Hosp Psychiatry. 1990;12(1):30–35.Google Scholar
35.Goggins, K, Engelson, ES, Rabkin, JG, Kolter, D. The relationship of mood, endocrine, and sexual disorders in human immunodeficiency virus positive (HIV+) women: an exploratory study. Psychosom Med. 1998;60(1):11–16.Google Scholar
36.Rabkin, JG, Wagner, GJ, Rabkin, R. Fluoxetine treatment for depression in patients with HIV and AIDS: A randomized, placebo-controlled trial. Am J Psychiatry. 1999;156(1):101–107.Google Scholar
37.Judd, FK, Mijch, AM, Cockram, A. Fluoxetine treatment of depressed patients with HIV infection. Aust N Z J Psychiatry. 1995;29(3):433–436.Google Scholar
38.Rabkin, JG, Rabkin, R, Wagner, G. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness. J Clin Psychiatry. 1994;55(3):92–97.Google Scholar
39.Grassi, B, Gambini, O, Scarone, S. Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects. Pharmacopsychiatry. 1995;28(3):93–94.Google Scholar
40.Fernandez, F, Levy, JK, Samley, HR, et al.Effects of methylphenidate in HIV-related depression: A comparative trial with desipramine. Int J Psychiatry Med. 1995;25(1):53–67.Google Scholar
41.Elliott, AJ, Uldall, KK, Bergam, K, Russo, J, Claypoole, K, Roy-Byrne, PP. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients. Am J Psychiatry. 1998;155(3):367–372.Google Scholar
42.McDaniel, JS, Musselman, DL, Porter, MR, Reed, DA, Nemeroff, CB. Depression in patients with cancer. diagnosis, biology, and treatment. Arch Gen Psychiatry. 1995;52(2):89–99.Google Scholar
43.Evans, DL, Staab, JP, Petitto, JM, et al.Depression in the medical setting: biopsychological interactions and treatment considerations. J Clin Psychiatry. 1999;60(suppl 40):40–55.Google Scholar
44.Spiegel, D, Sands, S, Koopman, C. Pain and depression in patients with cancer. Cancer. 1994;74(9):2570–2578.Google Scholar
45.Carroll, BT, Kathol, RG, Noyes, R Jr, Wald, TG, Clamon, GH. Screening for depression and anxiety in cancer patients using the hospital anxiety and depression scale. Gen Hosp Psychiatry. 1993;15(2):69–74.Google Scholar
46.Musselman, DL, Lawson, DH, Gumnick, JF, et al.Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961–966.Google Scholar
47.Borden, EC, Parkinson, D. A perspective on the clinical effectiveness and tolerance of interferon-alpha. Semin Oncol. 1998;25(1Suppl 1):3–8.Google Scholar
48.Frank, E, Prien, RF, Jarrett, RB, et al.Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851–855.Google Scholar
49.Kupfer, DJ, Frank, JM, Perel, CC, et al.Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1992;49:769–773.Google Scholar
50.Maes, M, Meltzer, HY. The serotonin hypothesis of major depression. In: Bloom, FE, Kuper, DJ, eds. Psychopharmacology: the Fourth Generation of Progress. 4th ed. New York, NY: Raven Press; 1195: 933–944.Google Scholar
51.Golden, RN, Heine, AD, Ekstrom, RD, Bebchuk, JM, Leatherman, ME, Garbutt, JC. A longitudinal study of serotonergic function in depression. Neuropsychopharmacology. 2002;26(5):653–659.Google Scholar
52.Anderson, JM, Ware, CJ, da Roza Davis, JM, Cowen, PJ. Decreased 5-HT-mediated prolactin release in major depression. Br J Psychiatry. 1992;160:372–378.Google Scholar
53.Golden, RN, Hsiao, J, Lane, E, et al.Abnormal neuroendocrine responsivity to acute intravenous clomipramine challenge in depressed patients. Psychiatry Res. 1990;31:39–47.Google Scholar
54.Golden, RN, Ekstrom, D, Brown, TB, et al.Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am J Psychiatry. 1992;149:1168–1175.Google Scholar
55.Golden, RN, Ruegg, R, Brown, T, Haggerty, J Jr, Garbutt, JC, Pedersen, C, Evans DL: Abnormal neuroendocrine responsivity to clomipramine in depression. Psychopharmacol Bull. 1990;26:317–320.Google Scholar
56.Kapitany, T, Schindl, M, Schindler, SD, et al.The citalopram challenge test in patients with major depression and in healthy controls. Psychiatry Res. 1999;88(2):75–88.Google Scholar
57.Sher, L, Oquendo, MA, Li, S, Prolactin response to fenfluramine administration in patients with unipolar and bipolar depression and healthy controls. Psychoneuroendocrinology. 2003;28(4):559–573.Google Scholar
58.Katon, W, Robinson, P, Von Korff, M, et al.A multifacted intervention to improved treatment of depression in primary care. Arch Gen Psychiatry. 1996;53(10): 924–932.Google Scholar
59.Lin, EHB, Von Korff, M, Katon, W, et al.The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33(1):67–74.Google Scholar
60.Katon, W, von Korff, M, Lin, E, Bush, T, Ormel, J. Adequacy and duration of antidepressant treatment in primary care. Med Care. 1992;30(1):67–76.Google Scholar
61.Clayton, AH, Pradko, JF, Croft, HA, et al.Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63(4):357–366.Google Scholar
62.Bennie, EH, Mullin, JM, Martindale, JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1995;56(6):229–237.Google Scholar
63.Schone, W, Ludwig, M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol. 1993;13(6 suppl 2):34S–39S.Google Scholar
64.Rothchild, AJ. Sexual side effects of antidepressants. J Clin Psychiatry. 2000;61(11):28–35.Google Scholar
65.Baldwin, DS, Thomas, SC, Brirtwistle, J. Effects of antidepressant drugs on sexual function. Int J Psychiatr Clin Pract. 1997;1:47–58.Google Scholar
66.Steffens, DC, Krishnan, KRK, Helms, MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-Analysis. Depress Anxiety. 1997;6:10–18.Google Scholar
67.Beasley, CM, Koke, SC, Nilsson, ME, Gonzales, JS. Adverse events and treatment discontinuation in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther. 2000;22(11):1319–1330.Google Scholar
68.Golden, RN, Nemeroff, CB, McSorley, P, Pitts, CD, Dubé, EM. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry. 2002;63:577–584.Google Scholar
69.Lepola, U, Bergtholdt, B, St Lambert, J, Davy, KL, Ruggiero, L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry. 2004;65(2):222–229.Google Scholar
70.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar